Predict your next investment

FOOD & BEVERAGES | Ingredients, flavoring & condiments
jennewein-biotech.de

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$17.5M

Valuation

$0000 

About Jennewein Biotechnologie

Jennewein Biotechnologie is a Rheinbreitbach, Germany-based industrial biotechnology company that manufactures a portfolio of HMO products, such as 2'-fucosyllactose, 3'-fucosyllactose and lacto-N-tetraose. These rare sugars are used in the food industry (particularly infant milk formulas), the pharmaceutical industry, and the cosmetic industry.On September 22nd, 2020, Jennewein Biotechnologie was acquired by Chr. Hansen at a valuation of $362.62M.

Jennewein Biotechnologie Headquarter Location

Maarweg 32

Rheinbreitbach, 53619,

Germany

Latest Jennewein Biotechnologie News

Chr. Hansen and Nestlé settles HMO patent litigation

May 17, 2021

Hansen and Nestlé have settled a legal dispute involving alleged infringements on Human Milk Oligosaccharide (HMO) patents arising from October 2020’s acquisition of Jennewein Biotechnologie. In a press statement by Chr Hansen, the firm agreed to withdraw ongoing litigation in Mannheim, Germany with Nestlé withdrawing the pending oppositions against the disputed patent rights. The Hørsholm-based bioscience company did not disclose any further details of the settlement agreement, when invited to comment. “Chr. Hansen intends to maintain and expand the acquired portfolio of intellectual property rights covering HMOs and the production hereof and will keep enforcing such IP rights,” ​they said in the statement. Start of dispute​ The dispute’s origins began in January 2020, when Jennewein requested a court injunction to prevent Nestlé selling infant formula products that contained specific HMOs from a third-party supplier. Jennewein believed the unnamed supplier was infringing on some of Jennewein’s patents and as such Nestlé were also implicated by selling these infant formula products containing the HMOs in question. The products were part of Nestlé’s infant formula brand Beba Supreme, which contains the HMOs 2'-Fucosyllactose (2'-FL) and Lacto-N-Neotetraose (LNnT) purified by the patent-protected process. In addition, Jennewein claimed to have evidence that Nestle infant formulas marketed under different trade names also included the two HMOs produced by the purification method. Jennewein’s patent attorney Dr Andreas Hübel said the process was protected by the patents, EP 2896628 ​​​​ and EP 3131912 ​​​​, which describes a method for the purification of 2’-FL and LNnT from a fermentation broth. Chr Hansen pays €310m​ The dispute then took another twist in October 2020, when Chr. Hansen purchased Jennewein Biotechnologie in a €310m deal that merged the bioscience firm’s probiotic interests with the gains Jennewein made in the HMO market. With Chr Hansen’s probiotic bacteria offerings, such as LGG and BB-12, and the microbiome-related acquisitions of UAS Labs and HSO Health Care, the actions pointed to heightened interests by the firm in upgrading current infant formulas produced and what is currently available. The plan taps into a new premiumisation trend in infant formula that Chr. Hansen may be looking to capitalise on to create synergistic blends in the future. While the purchase of Jennewein gave them access to a strong HMO patent portfolio, Chr Hansen also inherited the ongoing litigation with Nestlé that appears to have been resolved this week. Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Jennewein Biotechnologie Patents

Jennewein Biotechnologie has filed 31 patents.

The 3 most popular patent topics include:

  • Carbohydrate chemistry
  • EC 2.4.1
  • Breastfeeding
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/29/2016

7/20/2021

EC 2.4.1, Carbohydrate chemistry, EC 3.2.1, Carbohydrates, Polysaccharides

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/29/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/20/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

EC 2.4.1, Carbohydrate chemistry, EC 3.2.1, Carbohydrates, Polysaccharides

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Jennewein Biotechnologie Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Jennewein Biotechnologie Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.